Research Article| Volume 43, ISSUE 4, P735-742, April 2017

Download started.


Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study

Published:January 16, 2017DOI:



      To evaluate the efficacy and the feasibility of SBRT for selected patients with isolated local recurrence of pancreatic cancer after radical surgery.


      A retrospective analysis was performed on patients treated with SBRT for isolated local recurrence from resected pancreatic adenocarcinoma, after multidisciplinary board evaluation. Prescription dose was 45 Gy in 6 fractions for all patients. Primary end-point was freedom from local progression (FFLP). Secondary end-points were overall survival (OS), progression free survival (PFS) and toxicity. Local control was defined according to RECIST criteria. Acute and late toxicity was scored according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.


      Between January 2011 and February 2015, 31 patients with isolated local recurrence of resected pancreatic cancer were treated with SBRT. Pancreato-duodenectomy (PD) was performed on 24 patients and distal pancreatectomy (DP) in 7 cases, all with radical resection (R0). Median local recurrence disease free interval (DFI) was 14 months. Median follow-up was 12 months. FFLP was 91% and 82% at 1 and 2-years, respectively. Median PFS was 9 months. Median OS was 18 months. At univariate analysis, OS was correlated with a DFI>18 months. No cases of acute G3 toxicity or greater occurred.


      SBRT seems to be an effective and safe therapeutic option for isolated local recurrence of pancreatic cancer after surgery. Encouraging local control rate, very low toxicity profile and effective pain control suggest the crucial role of SBRT in the treatment of these long-survivors selected patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Raimondi S.
        • Maisonneuve P.
        • Lowenfels A.
        Epidemiology of pancreatic cancer: an overview.
        Nat Rev Gastroenterol Hepatol. 2009; 6: 699-708
        • Siegel R.
        • Naishadham D.
        • Jemal A.
        Cancer statistics, 2013.
        CA Cancer J Clin. 2013; 63: 11-30
        • Van den Broeck A.
        • Sergeant G.
        • Ectors N.
        • et al.
        Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma.
        Eur J Surg Oncol. 2009; 35: 600
        • Zhang Y.
        • Frampton A.E.
        • Kyriakides C.
        • et al.
        Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy.
        J Cancer Res Clin Oncol. 2012; 138: 1063-1107
        • Kleeff J.
        • Reiser C.
        • Hinz U.
        • et al.
        Surgery for recurrent pancreatic ductal adenocarcinoma.
        Ann Surg. 2007; 245: 566-572
        • Habermehl D.
        • Brecht I.
        • Bergmann F.
        • et al.
        Chemoradiation in patients with isolated recurrent pancreatic cancer therapeutical efficacy and probability of re-resection.
        Radiat Oncol. 2013; 8: 27
        • Wilkowski R.
        • Thoma M.
        • Bruns C.
        • Wagner A.
        • Heinemann Vl
        Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
        JOP. 2006; 7: 34-40
        • Nakamura A.
        • Itasaka S.
        • Takaori K.
        • et al.
        Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer.
        Strahlenther Onkol. 2014; 190: 485-490
        • Brunner T.B.
        • Nestle U.
        • Grosu A.L.
        • Partidge M.
        SBRT in pancreatic cancer: what is the therapeutic windows?.
        Radiother Oncol. 2015; 114: 109-116
        • Tozzi A.
        • Comito T.
        • Alongi F.
        • et al.
        SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
        Radiat Oncol. 2013; 8: 148
        • Eisenhauer E.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Iacobuzio-Donahue C.
        • Fu B.
        • Yachida S.
        • et al.
        DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
        J Clin Oncol. 2009; 27: 1806-1813
        • Hernandez J.
        • Morton C.
        • Al-Saadi S.
        • et al.
        The natural history of resected pancreatic cancer without adjuvant chemotherapy.
        Am Surg. 2010; 76: 480e5
        • Zacharias T.
        • Oussoultzoglou E.
        • Jaeck D.
        • Pessaux P.
        • Bachellier P.
        Surgery for recurrence of periampullary malignancies.
        J Gastrointest Surg. 2009; 13: 760e7
        • Kim Y.
        • Seo D.
        • Pack K.
        • et al.
        The prognostic factors of pancreatic cancer can be different according to clinical stages.
        Korean J Gastroenterol. 2008; 51: 181e9
        • Morganti A.
        • Forni F.
        • Macchia G.
        • et al.
        Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure.
        Strahlenther Onkol. 2003; 179: 87e92
        • Crane C.
        • Varadhachary G.
        • Yordy J.
        • et al.
        Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression.
        JCO. 2011; 29: 22
        • Hashimoto K.
        • Ueno H.
        • Ikeda M.
        • et al.
        Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?.
        Oncology. 2009; 77: 217-223
        • Polistina F.
        • Costantin G.
        • Casamassima F.
        • et al.
        Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
        Ann Surg Oncol. 2010; 17: 2092-2101
        • Strobel O.
        • Hartwig W.
        • Hackert T.
        • et al.
        Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival.
        Ann Surg Oncol. 2013 Mar; 20: 964-972